Compare DOO & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOO | IDYA |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 2018 | 2019 |
| Metric | DOO | IDYA |
|---|---|---|
| Price | $61.18 | $33.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 16 |
| Target Price | ★ $70.75 | $52.38 |
| AVG Volume (30 Days) | 177.6K | ★ 806.6K |
| Earning Date | 12-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $4.43 | $188.45 |
| P/E Ratio | $338.95 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $48.83 | $26.81 |
| 52 Week High | $81.89 | $42.68 |
| Indicator | DOO | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 38.88 |
| Support Level | $59.56 | $29.74 |
| Resistance Level | $63.73 | $35.14 |
| Average True Range (ATR) | 1.75 | 1.46 |
| MACD | 0.94 | -0.07 |
| Stochastic Oscillator | 94.38 | 21.45 |
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested; Manitou was sold in the third quarter of fiscal 2026, and Telwater remains up for sale. At the end of fiscal 2026, BRP sold its products through a network of more than 2,050 independent dealers and 140 distributors in around 110 countries.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.